Jazz Pharmaceuticals (JAZZ) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Jazz Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$240.74-3.10(-0.01%)After hours

Market Cap

$15.21B

P/E

16.2x

P/S

3.3x

P/B

3.2x

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

How this company scores

ExcellentMetricSide Score: 84/100

Strongest: Cash & Earnings Quality (25/25); weakest: Balance Sheet & Red Flags (16/25).

Profitability22/25

Growth21/25

Balance Sheet & Red Flags16/25

Cash & Earnings Quality25/25

Strengths

Rising free cash flowStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 16.2x5y range 13.3x – 384.4x

Currently near its 9-quarter median.

P/S · 3.3x5y range 1.6x – 3.3x

Currently above its 20-quarter median.

P/B · 3.2x5y range 1.6x – 3.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Share Dilution

Watch

Shares outstanding rose 2.9% — mild dilution. Compare to earnings growth to assess the net per-share impact.

Price & Volume

Market Cap $15.21B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.60B
Q. Revenue: $1.21B
TTM EBITDA: $1.62B
TTM Op. Income: $896.84M
Q. Op. Income: $248.20M
TTM Net Income: $940.76M
Q. Net Income: $192.80M
EPS: $3.05
Shares Out.: $63.20M

$4.60B in TTM revenue grew 12.6% YoY, reaching $1.21B last quarter. TTM EBITDA of $1.62B and TTM operating income of $896.84M show growth is flowing through to the bottom line. TTM net income of $940.76M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 34.6%
Op. Margin: 20.5%
Net Margin: 16.0%

Op. margin of 20.5% is up 86.2% YoY — cost efficiency is improving. Net margin at 16.0% Over the past year, operating margin is up 131% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 16.2x
P/S Ratio: 3.3x
P/B Ratio: 3.2x

At 16.2x P/E, the stock trades within typical market levels. P/S of 3.3x and P/B of 3.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 9% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $11.08B
Cash: $1.62B
Long-Term Debt: $3.33B
Book Value: $4.80B
D/E Ratio: 0.7
Debt/EBITDA: 8.0

With $11.08B in assets and $3.33B in long-term debt, D/E is 0.7and book value is $4.80B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 6 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $415.70M
TTM Free Cash Flow: $1.59B
FCF Margin: 34.6%
FCF / Net Income: 1.7

TTM FCF of $1.59B on $415.70M in operating cash flow. The FCF / Net Income ratio of 1.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 26% — an improving trend.